国产盐酸洛美利嗪治疗偏头痛的系统评价

Effectiveness of domestic lomerizine hydrochloride in treatment of migraine: a Meta-analysis

目的评价国产盐酸洛美利嗪治疗偏头痛的疗效及安全性。方法计算机检索中国知网、万方数据库、维普网,检索时限为建库至2016年3月,筛选出有关国产盐酸洛美利嗪治疗偏头痛方面的随机对照试验文献,由两名研究员按照入选标准、排除标准独立筛选试验,并评价文献质量,提取相应的资料,然后采用Rev Man 5.3软件进行Meta分析。结果最终纳入9个随机对照研究,共计737例患者。Meta分析结果显示:(1)洛美利嗪组与安慰剂组总有效率的比较差异有统计学意义(RR=5.44,95%CI:3.56~8.30,P<0.01),洛美利嗪对偏头痛的疗效明显优于安慰剂治疗。(2)洛美利嗪组与其他药物组相比总有效率的比较差异无统计学意义(RR=1.06,95%CI:0.99~1.13,P>0.01),洛美利嗪对偏头痛的疗效与目前常用药物相当。(3)洛美利嗪不良反应发生率与安慰剂、其他药物相当(RR=0.68,95%CI:0.33~1.38)。结论国产盐酸洛美利嗪是安全有效防治偏头痛发作的药物。

Objective To evaluate of the curative effection of domestic lomerizine hydrochloride in treatment of migraine and its safety. Methods Such database as CNKI, VIP, Wan Fang Data were electronically researched to collect the randomized controlled trials(RCTs) about lomerizine hydrochloride treating patients with migraine from the dates of their establishment to March 2016. Two reviewers independently screened literature according to the inclusion and exclusion criteria, and evaluated the quality of the included studies, extracted the date. Meta-analysis was performed by using Rev Man 5.3 software. Results Nine RCTs involving 737 cases were included. The result of Meta-analysis showed that the curative effect of lomerizineon was significantly superior to placebo in the treatment of migraine(RR=5.44, 95% CI: 3.56-8.30, P<0.01); while efficacy of lomerizineon on migraine was equivalent to currently used drugs(RR=1.06, 95% CI: 0.99-1.13, P>0.01). The rate of adverse events was similar with placebo and comparisons(RR=0.68, 95% CI: 0.33-1.38). Conclusion Domestic lomerizine hydrochlorideis a safe and effective drug to prevent migraine attacks.